Med Fusion Named Roche Molecular Center of Excellence | GenomeWeb

NEW YORK (GenomeWeb News) – Roche today said that med fusion, a Lewisville, Texas-based clinical lab and clinical trials services firm, has been named a Roche Molecular Center of Excellence for the next five years.

As part of the designation, med fusion will offer a range of Roche's molecular technologies including the cobas 4800 V600 Mutation Test, a companion diagnostic approved by the US Food and Drug Administration last year for identifying patients who are eligible for treatment with the drug Zelboraf (vemurafenib) for inoperable or metastatic melanoma.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.

The San Diego Union-Tribune takes a look at the work to be done in personalized medicine.

An op-ed in the Wall Street Journal calls for the establishment of a patent court staffed by judges and experts with science backgrounds.

In PLOS this week: variants that affect COPD biomarkers, high genetic diversity of Cryptococcus gattii in Brazil, and more.